息斯敏(astemizole)是一种无镇静作用的新型抗组胺药,我们于1988年进行了本品治疗荨麻疹的双盲安慰剂对照试验。在此基础上,又进行了长疗程开放试验和皮肤试验风团反应抑制作用的研究,对本品的疗效和不良反应进行了综合评价。 1 资料和方法 1.1 短疗程的双盲安慰剂对照试验 1.1.1 病例选择经临床确诊的各型急、慢性荨麻疹患者,年龄为12～16岁,男女不限。投药前3天停用一切抗组胺药、镇静剂和皮质激素。肝肾功能不正 Astemizole is a non-sedating new antihistamine. We conducted a double-blind placebo-controlled trial of urticaria in 1988. On this basis, we conducted a long course of open test and skin test wind group reaction inhibitory effect of this product efficacy and adverse reactions were comprehensively evaluated. 1 Materials and Methods 1.1 Short-course, double-blind, placebo-controlled trial 1.1.1 Case Selection Clinical diagnosis of various types of patients with acute and chronic urticaria, aged 12 to 16 years old, male or female. 3 days prior to the withdrawal of all antihistamines, sedatives and corticosteroids. Liver and kidney dysfunction